within Pharmacolibrary.Drugs.ATC.D;

model D07AC12
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D07AC12</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Halometasone is a potent synthetic corticosteroid used for its anti-inflammatory, antipruritic, and vasoconstrictive properties. It is primarily used topically for the treatment of various skin disorders such as eczema, dermatitis, and psoriasis. Halometasone is not approved in the United States or many Western countries but is used in some countries for dermatological indications.</p><h4>Pharmacokinetics</h4><p>No published clinical pharmacokinetic studies for halometasone in humans are available. Estimates below are based on class properties of potent topical corticosteroids.</p><h4>References</h4><ol><li><p>Asche, H, et al., &amp; Weirich, EG (1985). Influence of formulation factors on the availability of drugs from topical preparations. <i>Pharmaceutica acta Helvetiae</i> 60(8) 232–237. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4070318/&quot;>https://pubmed.ncbi.nlm.nih.gov/4070318</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D07AC12;
